Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 3, 2015

Study Completion Date

August 3, 2015

Conditions
Advanced Ovarian CarcinomaPrimary Peritoneal CarcinomaOvarian Carcinosarcoma
Interventions
DRUG

Avastin

"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"

DRUG

Paclitaxel

Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles

DRUG

Cisplatin

75mg/m2 IP day 2 every 21 days x 6 cycles

Trial Locations (1)

73104

University of Oklahoma Health Sciences Center, Oklahoma City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Oklahoma

OTHER

NCT00511992 - Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | Biotech Hunter | Biotech Hunter